Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus

Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Medical journal of Malaysia 2012-02, Vol.67 (1), p.21-24
Hauptverfasser:	Lim, P C, Lim, S L, Oiyammaal, C
Format:	Artikel
Sprache:	eng
Schlagworte:	Blood Glucose - analysis Costs and Cost Analysis Diabetes Mellitus, Type 2 - drug therapy Drug Therapy, Combination Female Gliclazide - administration & dosage Glyburide - administration & dosage Glycated Hemoglobin A - analysis Humans Hypoglycemic Agents - administration & dosage Male Metformin - administration & dosage Middle Aged Retrospective Studies Tablets
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	24
container_issue	1
container_start_page	21
container_title	Medical journal of Malaysia
container_volume	67
creator	Lim, P C Lim, S L Oiyammaal, C
description	Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost following the change. Eighty patients (60% females) with a mean age of 55 years old were studied. Mean glycosylated haemoglobin (HbAlc) reduction was -0.92% (p
format	Article
fullrecord	<record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_1013926468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1013926468</sourcerecordid><originalsourceid>FETCH-LOGICAL-p126t-f04b5eb820b2ebf84d97b91dce4a84153aa367273890ce98167f3a2712645e53</originalsourceid><addsrcrecordid>eNpNkE1LxDAQhntQ3GXdvyA5eim0SdOmR1l0FRa87L3kY7obyUdNUpb6m_yRRlRwLvMy87wvw1wV64pUVUkxI6tiG-NblauledjeFCuMKcO0adbF594skoPVEknvUvAGcaeyjikLbpaoI7qcwSF55u6k3QmNwVt0Mloa_qEVZLbkymqnY4IACl10OiMLafQhT1HyaApQSm-FdnmdnQJcNttsLv9xXBhIEX3LZQKEkdJcQIKYw4zRaY63xfXITYTtb98Ux6fH4-65PLzuX3YPh3KqcZvKsWoEBcFwJTCIkTWq70RfKwkNZ01NCeek7XBHWF9J6FnddiPhuMvmhgIlm-L-J3YK_n2GmAaro8w3cAd-jkNd1aTPbMsyeveLzsKCGqagLQ_L8Pdg8gVhinr4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1013926468</pqid></control><display><type>article</type><title>Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Lim, P C ; Lim, S L ; Oiyammaal, C</creator><creatorcontrib>Lim, P C ; Lim, S L ; Oiyammaal, C</creatorcontrib><description>Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost following the change. Eighty patients (60% females) with a mean age of 55 years old were studied. Mean glycosylated haemoglobin (HbAlc) reduction was -0.92% (p<0.01) and -0.83% (p<0.01) after three and six months respectively. Patients with baseline HbA1c > or =8% had greater reduction in mean HbA1c (-1.36%) after six months. The treatment cost per month was reduced by 45% at 3 months (p<0.01)) and 44% at 6 months (p<0.01). The change to pre-combined glibenclamide-metformin tablets resulted in significant improvement in glycaemia and reduction in treatment cost</description><identifier>ISSN: 0300-5283</identifier><identifier>PMID: 22582544</identifier><language>eng</language><publisher>Malaysia</publisher><subject>Blood Glucose - analysis ; Costs and Cost Analysis ; Diabetes Mellitus, Type 2 - drug therapy ; Drug Therapy, Combination ; Female ; Gliclazide - administration & dosage ; Glyburide - administration & dosage ; Glycated Hemoglobin A - analysis ; Humans ; Hypoglycemic Agents - administration & dosage ; Male ; Metformin - administration & dosage ; Middle Aged ; Retrospective Studies ; Tablets</subject><ispartof>Medical journal of Malaysia, 2012-02, Vol.67 (1), p.21-24</ispartof><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22582544$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lim, P C</creatorcontrib><creatorcontrib>Lim, S L</creatorcontrib><creatorcontrib>Oiyammaal, C</creatorcontrib><title>Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus</title><title>Medical journal of Malaysia</title><addtitle>Med J Malaysia</addtitle><description>Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost following the change. Eighty patients (60% females) with a mean age of 55 years old were studied. Mean glycosylated haemoglobin (HbAlc) reduction was -0.92% (p<0.01) and -0.83% (p<0.01) after three and six months respectively. Patients with baseline HbA1c > or =8% had greater reduction in mean HbA1c (-1.36%) after six months. The treatment cost per month was reduced by 45% at 3 months (p<0.01)) and 44% at 6 months (p<0.01). The change to pre-combined glibenclamide-metformin tablets resulted in significant improvement in glycaemia and reduction in treatment cost</description><subject>Blood Glucose - analysis</subject><subject>Costs and Cost Analysis</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Gliclazide - administration & dosage</subject><subject>Glyburide - administration & dosage</subject><subject>Glycated Hemoglobin A - analysis</subject><subject>Humans</subject><subject>Hypoglycemic Agents - administration & dosage</subject><subject>Male</subject><subject>Metformin - administration & dosage</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Tablets</subject><issn>0300-5283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1LxDAQhntQ3GXdvyA5eim0SdOmR1l0FRa87L3kY7obyUdNUpb6m_yRRlRwLvMy87wvw1wV64pUVUkxI6tiG-NblauledjeFCuMKcO0adbF594skoPVEknvUvAGcaeyjikLbpaoI7qcwSF55u6k3QmNwVt0Mloa_qEVZLbkymqnY4IACl10OiMLafQhT1HyaApQSm-FdnmdnQJcNttsLv9xXBhIEX3LZQKEkdJcQIKYw4zRaY63xfXITYTtb98Ux6fH4-65PLzuX3YPh3KqcZvKsWoEBcFwJTCIkTWq70RfKwkNZ01NCeek7XBHWF9J6FnddiPhuMvmhgIlm-L-J3YK_n2GmAaro8w3cAd-jkNd1aTPbMsyeveLzsKCGqagLQ_L8Pdg8gVhinr4</recordid><startdate>201202</startdate><enddate>201202</enddate><creator>Lim, P C</creator><creator>Lim, S L</creator><creator>Oiyammaal, C</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201202</creationdate><title>Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus</title><author>Lim, P C ; Lim, S L ; Oiyammaal, C</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p126t-f04b5eb820b2ebf84d97b91dce4a84153aa367273890ce98167f3a2712645e53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Blood Glucose - analysis</topic><topic>Costs and Cost Analysis</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Gliclazide - administration & dosage</topic><topic>Glyburide - administration & dosage</topic><topic>Glycated Hemoglobin A - analysis</topic><topic>Humans</topic><topic>Hypoglycemic Agents - administration & dosage</topic><topic>Male</topic><topic>Metformin - administration & dosage</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Tablets</topic><toplevel>online_resources</toplevel><creatorcontrib>Lim, P C</creatorcontrib><creatorcontrib>Lim, S L</creatorcontrib><creatorcontrib>Oiyammaal, C</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Medical journal of Malaysia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lim, P C</au><au>Lim, S L</au><au>Oiyammaal, C</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus</atitle><jtitle>Medical journal of Malaysia</jtitle><addtitle>Med J Malaysia</addtitle><date>2012-02</date><risdate>2012</risdate><volume>67</volume><issue>1</issue><spage>21</spage><epage>24</epage><pages>21-24</pages><issn>0300-5283</issn><abstract>Type-2 diabetes mellitus (T2DM) patients who were on gliclazide co-administered with metformin were changed to pre-combined glibenclamide-metformin tablets in the Endocrine Clinic, Penang Hospital. We conducted a retrospective study to evaluate the differences in glycaemic control and treatment cost following the change. Eighty patients (60% females) with a mean age of 55 years old were studied. Mean glycosylated haemoglobin (HbAlc) reduction was -0.92% (p<0.01) and -0.83% (p<0.01) after three and six months respectively. Patients with baseline HbA1c > or =8% had greater reduction in mean HbA1c (-1.36%) after six months. The treatment cost per month was reduced by 45% at 3 months (p<0.01)) and 44% at 6 months (p<0.01). The change to pre-combined glibenclamide-metformin tablets resulted in significant improvement in glycaemia and reduction in treatment cost</abstract><cop>Malaysia</cop><pmid>22582544</pmid><tpages>4</tpages></addata></record>
fulltext	fulltext
identifier	ISSN: 0300-5283
ispartof	Medical journal of Malaysia, 2012-02, Vol.67 (1), p.21-24
issn	0300-5283
language	eng
recordid	cdi_proquest_miscellaneous_1013926468
source	MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects	Blood Glucose - analysis Costs and Cost Analysis Diabetes Mellitus, Type 2 - drug therapy Drug Therapy, Combination Female Gliclazide - administration & dosage Glyburide - administration & dosage Glycated Hemoglobin A - analysis Humans Hypoglycemic Agents - administration & dosage Male Metformin - administration & dosage Middle Aged Retrospective Studies Tablets
title	Glycaemic control and cost analysis when changing from gliclazide co-administered with metformin to pre-combined glibenclamide-metformin tablets in type 2 diabetes mellitus
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T23%3A03%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Glycaemic%20control%20and%20cost%20analysis%20when%20changing%20from%20gliclazide%20co-administered%20with%20metformin%20to%20pre-combined%20glibenclamide-metformin%20tablets%20in%20type%202%20diabetes%20mellitus&rft.jtitle=Medical%20journal%20of%20Malaysia&rft.au=Lim,%20P%20C&rft.date=2012-02&rft.volume=67&rft.issue=1&rft.spage=21&rft.epage=24&rft.pages=21-24&rft.issn=0300-5283&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E1013926468%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1013926468&rft_id=info:pmid/22582544&rfr_iscdi=true